Table 4.
Patients requiring the addition of analgesic/NSAID
| Parameters | Group I | Group II | |
|---|---|---|---|
| Cephalexin CV n = 174 |
Cefuroxime n = 87 |
Co-amoxiclav n = 94 |
|
| Proportion of patients using first analgesic | 167 (95.9%) | 74 (85.1%) | 93 (98.9%) |
| Duration of (first) analgesic/NSAID use; days | |||
| Mean ± SD | 5.8 ± 2.5 | 6.0 ± 2.7 | 6.1 ± 2.5 |
| Median (range) | 5 (2–19) | 5 (2–16) | 5 (3–16) |
| Proportion of patients using second analgesic | 14 (8.1%) | 7 (8.1%) | 6 (6.4%) |
| Duration of (second) analgesic/NSAID use; days | |||
| Mean ± SD | 4.8 ± 0.5 | 5.0. ± 0.0 | 4.8 ± 2.2 |
| Median (range) | 5 (3–5) | 5 (5–5) | 4 (3–8) |
CV clavulanic acid, co-amoxiclav amoxicillin–clavulanic acid, n number of patients, NSAID nonsteroidal anti-inflammatory drug, SD standard deviation